Condition
Mesothelioma|Lung Cancer
Estimated Enrollment: 662
Age Group: 18 Years and older (Adult, Senior)
Gender: All
Study Type: Interventional
Study Design Allocation: Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Treatment
Study ID Numbers: 0683-014|2005_010|CTRI/2009/091/000146
Study First Received: August 5, 2005
Last Updated: April 17, 2015
Estimated Primary Completion Date: July 2011
Primary Outcome Measures:
Overall survival|Number of participants with adverse events characterized as Grade 3/4 according to the National Cancer Institute (NCI) Common Terminology for Adverse Events (CTCAE)|Progression-free survival|Objective response rate|Percent change from baseline in dyspnea score of the Lung Cancer Symptom Scale modified for mesothelioma (LCSS-Meso)|Percent change from baseline in forced vital capacity (FVC)
Sponsors and Collaborators:
Merck Sharp & Dohme Corp.
Website Link: https://ClinicalTrials.gov/show/NCT00128102
